|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Shkumatava A, Stark A, Sive H and Bartel
DP: Coherent but overlapping expression of microRNAs and their
targets during vertebrate development. Genes Dev. 23:466–481. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma F, Song H, Guo B, Zhang Y, Zheng Y, Lin
C, Wu Y, Guan G, Sha R, Zhou Q, et al: miR-361-5p inhibits
colorectal and gastric cancer growth and metastasis by targeting
staphylococcal nuclease domain containing-1. Oncotarget.
6:17404–17416. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ozen M, Karatas OF, Gulluoglu S, Bayrak
OF, Sevli S, Guzel E, Ekici ID, Caskurlu T, Solak M, Creighton CJ
and Ittmann M: Overexpression of miR-145-5p inhibits proliferation
of prostate cancer cells and reduces SOX2 expression. Cancer
Invest. 33:251–258. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ni F, Zhao H, Cui H, Wu Z, Chen L, Hu Z,
Guo C, Liu Y, Chen Z, Wang X, et al: MicroRNA-362-5p promotes tumor
growth and metastasis by targeting CYLD in hepatocellular
carcinoma. Cancer Lett. 356:809–818. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Organista-Nava J, Gómez-Gómez Y,
Illades-Aguiar B, Del Carmen Alarcón-Romero L, Saavedra-Herrera MV,
Rivera-Ramírez AB, Garzón-Barrientos VH and Leyva-Vázquez MA: High
miR-24 expression is associated with risk of relapse and poor
survival in acute leukemia. Oncol Rep. 33:1639–1649. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shen H, Shen J, Wang L, Shi Z, Wang M,
Jiang BH and Shu Y: Low miR-145 expression level is associated with
poor pathological differentiation and poor prognosis in non-small
cell lung cancer. Biomed Pharmacother. 69:301–305. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vilquin P, Donini CF, Villedieu M, Grisard
E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b
upregulation confers aromatase inhibitor resistance and is a novel
marker of poor prognosis in breast cancer. Breast Cancer Res.
17:132015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao H, Dong T, Zhou H, Wang L, Huang A,
Feng B, Quan Y, Jin R, Zhang W, Sun J, et al: miR-320a suppresses
colorectal cancer progression by targeting Rac1. Carcinogenesis.
35:886–895. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang Y, He X, Liu Y, Ye Y, Zhang H, He P,
Zhang Q, Dong L, Liu Y and Dong J: microRNA-320a inhibits tumor
invasion by targeting neuropilin 1 and is associated with liver
metastasis in colorectal cancer. Oncol Rep. 27:685–694.
2012.PubMed/NCBI
|
|
12
|
Sun JY, Huang Y, Li JP, Zhang X, Wang L,
Meng YL, Yan B, Bian YQ, Zhao J, Wang WZ, et al: MicroRNA-320a
suppresses human colon cancer cell proliferation by directly
targeting β-catenin. Biochem Biophys Res Commun. 420:787–792. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qi X, Li J, Zhou C, Lv C and Tian M:
MicroRNA-320a inhibits cell proliferation, migration and invasion
by targeting BMI-1 in nasopharyngeal carcinoma. FEBS Lett.
588:3732–3738. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang B, Yang Z, Wang H, Cao Z, Zhao Y,
Gong C, Ma L, Wang X, Hu X and Chen S: MicroRNA-320a inhibits
proliferation and invasion of breast cancer cells by targeting
RAB11A. Am J Cancer Res. 5:2719–2729. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li X, Lu Y, Chen Y, Lu W and Xie X:
MicroRNA profile of paclitaxel-resistant serous ovarian carcinoma
based on formalin-fixed paraffin-embedded samples. BMC Cancer.
13:2162013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lü M, Ding K, Zhang G, Yin M, Yao G, Tian
H, Lian J, Liu L, Liang M, Zhu T and Sun F: MicroRNA-320a
sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by
targeting ARPP-19 and ERRγ. Sci Rep. 5:87352015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lian F, Cui Y, Zhou C, Gao K and Wu L:
Identification of a plasma four-microRNA panel as potential
noninvasive biomarker for osteosarcoma. PLoS One. 10:e01214992015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wen Y, Han J, Chen J, Dong J, Xia Y, Liu
J, Jiang Y, Dai J, Lu J, Jin G, et al: Plasma miRNAs as early
biomarkers for detecting hepatocellular carcinoma. Int J Cancer.
137:1679–1690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fang Z, Tang J, Bai Y, Lin H, You H, Jin
H, Lin L, You P, Li J, Dai Z, et al: Plasma levels of microRNA-24,
microRNA-320a, and microRNA-423-5p are potential biomarkers for
colorectal carcinoma. J Exp Clin Cancer Res. 34:862015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
You B, Shan Y, Shi S, Li X and You Y:
Effects of ADAM10 upregulation on progression, migration, and
prognosis of nasopharyngeal carcinoma. Cancer Sci. 106:1506–1514.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Arima T, Enokida H, Kubo H, Kagara I,
Matsuda R, Toki K, Nishimura H, Chiyomaru T, Tatarano S, Idesako T,
et al: Nuclear translocation of ADAM-10 contributes to the
pathogenesis and progression of human prostate cancer. Cancer Sci.
98:1720–1726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gaida MM, Haag N, Günther F, Tschaharganeh
DF, Schirmacher P, Friess H, Giese NA, Schmidt J and Wente MN:
Expression of A disintegrin and metalloprotease 10 in pancreatic
carcinoma. Int J Mol Med. 26:281–288. 2010.PubMed/NCBI
|
|
23
|
Jones AV, Lambert DW, Speight PM and
Whawell SA: ADAM 10 is over expressed in oral squamous cell
carcinoma and contributes to invasive behaviour through a
functional association with αvβ6 integrin. FEBS Lett.
587:3529–3534. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pan Y, Han C, Wang C, Hu G, Luo C, Gan X,
Zhang F, Lu Y and Ding X: ADAM10 promotes pituitary adenoma cell
migration by regulating cleavage of CD44 and L1. J Mol Endocrinol.
49:21–33. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Guo J, He L, Yuan P, Wang P, Lu Y, Tong F,
Wang Y, Yin Y, Tian J and Sun J: ADAM10 overexpression in human
non-small cell lung cancer correlates with cell migration and
invasion through the activation of the Notch1 signaling pathway.
Oncol Rep. 28:1709–1718. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang CL, Jiang FQ, Xu F and Jiang GX:
ADAM10 overexpression confers resistance to doxorubicin-induced
apoptosis in hepatocellular carcinoma. Tumour Biol. 33:1535–1541.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jing P, Sa N, Liu X, Liu X and Xu W:
MicroR-140-5p suppresses tumor cell migration and invasion by
targeting ADAM10-mediated Notch1 signaling pathway in
hypopharyngeal squamous cell carcinoma. Exp Mol Pathol.
100:132–138. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ergün S, Ulasli M, Igci YZ, Igci M,
Kırkbes S, Borazan E, Balik A, Yumrutaş Ö, Camci C, Cakmak EA, et
al: The association of the expression of miR-122-5p and its target
ADAM10 with human breast cancer. Mol Biol Rep. 42:497–505. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guo T, Feng Y, Liu Q, Yang X, Jiang T,
Chen Y and Zhang Q: MicroRNA-320a suppresses in GBM patients and
modulates glioma cell functions by targeting IGF-1R. Tumour Biol.
35:11269–11275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Salendo J, Spitzner M, Kramer F, Zhang X,
Jo P, Wolff HA, Kitz J, Kaulfuß S, Beißbarth T, Dobbelstein M, et
al: Identification of a microRNA expression signature for
chemoradiosensitivity of colorectal cancer cells, involving
miRNAs-320a, −224, −132 and let7g. Radiother Oncol. 108:451–457.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao X, Shen K, Wang C, Ling J, Wang H,
Fang Y, Shi Y, Hou Y, Qin J, Sun Y and Qin X: MiR-320a
downregulation is associated with imatinib resistance in
gastrointestinal stromal tumors. Acta Biochim Biophys Sin
(Shanghai). 46:72–75. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Przemyslaw L, Boguslaw HA, Elzbieta S and
Malgorzata SM: ADAM and ADAMTS family proteins and their role in
the colorectal cancer etiopathogenesis. BMB Rep. 46:139–150. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang YY, Ye ZY, Li L, Zhao ZS, Shao QS and
Tao HQ: ADAM 10 is associated with gastric cancer progression and
prognosis of patients. J Surg Oncol. 103:116–123. 2011. View Article : Google Scholar : PubMed/NCBI
|
